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Diversified neurons are essential for sensorimotor
function, but whether astrocytes become specialized
to optimize circuit performance remains unclear.
Large fast a-motor neurons (FaMNs) of spinal cord
innervate fast-twitch muscles that generate peak
strength. We report that ventral horn astrocytes
express the inward-rectifying K+ channel Kir4.1
(a.k.a. Kcnj10) around MNs in a VGLUT1-dependent
manner. Loss of astrocyte-encodedKir4.1 selectively
altered FaMN size and function and led to reduced
peak strength. Overexpression of Kir4.1 in astrocytes
was sufficient to increase MN size through activation
of the PI3K/mTOR/pS6 pathway. Kir4.1 was downre-
gulated cell autonomously in astrocytes derived from
amyotrophic lateral sclerosis (ALS) patients with
SOD1 mutation. However, astrocyte Kir4.1 was
dispensable for FaMN survival even in the mutant
SOD1 background. These findings show that astro-
cyte Kir4.1 is essential for maintenance of peak
strength and suggest that Kir4.1 downregulation
might uncouple symptoms of muscle weakness
from MN cell death in diseases like ALS.
INTRODUCTION
Astrocytes (AS) carry out general functions in the central nervous
system (CNS), including blood-brain barrier formation, regulation
of synaptogenesis, and themaintenance of metabolic, ionic, and306 Neuron 98, 306–319, April 18, 2018 ª 2018 The Authors. Publish
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2009; Matyash and Kettenmann, 2010). Because AS are perva-
sive throughout the CNS and their processes tile within domains,
they are key environmental determinants for neural circuits.
We have proposed that regionally diversified AS could become
‘‘optimized’’ to enhance local function (Freeman and Rowitch,
2013; Molofsky et al., 2012). Indeed, differences in AS
morphology (Oberheim et al., 2012) and transcriptional profiles
(Cahoy et al., 2008; Doyle et al., 2008; Zhang et al., 2014) suggest
that AS comprise distinct classes with potentially varied
regional activities (Ben Haim and Rowitch, 2017; Khakh and
Sofroniew, 2015). Coordination of voluntary movement is com-
plex and requires diversified motor neuron (MN) subtypes that
form region- and muscle-specific interactions (Kanning et al.,
2010). Pattern formation underlies generation of MN diversity
(Stifani, 2014), and a similar region-restricted developmental
mechanism is associated with specification and regional
allocation of AS (Hochstim et al., 2008; Muroyama et al., 2005;
Tsai et al., 2012). However, the relationship between local
AS specialization, neuron subtype selective support, and neural
circuit function remains poorly understood.
Spinal cord aMNs fall into two broad classes along the anterior
posterior axis. Slow aMNs (SaMNs) innervate type I muscle fibers
and generate fatigue-resistant, low-force contractions while
fast aMNs (FaMNs) project to type II fast-fatigable muscle
fibers and produce brief, but high force outputs (Burke et al.,
1971; Eccles et al., 1957). Gamma MNs (gMNs) innervate
muscle spindles to ensure proper muscle fiber tension.
The morphological, transcriptional, and biophysical properties
of these MN subtypes match their corresponding muscle
contractile properties (Henneman, 1957; Kernell, 1966; M€uller
et al., 2014). FaMNs are larger in size, are activated at
higher thresholds, and fire action potentials in high-frequencyed by Elsevier Inc.
commons.org/licenses/by/4.0/).
bursts that are readily distinguishable from SaMNs (Hadzipasic
et al., 2014).
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disease characterized by progressive muscle weakness and
paralysis resulting from MN death (Cleveland and Rothstein,
2001). Although the majority of cases are sporadic, familial forms
of ALS have provided insight into genetic causes of the disease
(Robberecht and Philips, 2013). Of these, constitutive mutations
of superoxide dismutase 1 (SOD1) (Rosen, 1993) have been the
most extensively studiedandare sufficient to causeclinical symp-
toms and MN death in rodent models (Philips and Rothstein,
2015). FaMNs innervating fast-fatigable muscle fibers are selec-
tively vulnerable in ALS (Saxena and Caroni, 2011). In SOD1G93A
transgenic ALS mice, these MNs display early transcriptional
alterations and endoplasmic reticulum (ER) stress (Saxena
et al., 2009) and selectively express matrix metalloproteinase-9
(MMP-9),which regulates FaMNsurvival anddiseaseprogression
(Kaplan et al., 2014). Indeed, FaMN cell death in ALS is generally
thought to cause loss of peak strength and clinical decline in both
rodent models and human patients (Kanning et al., 2010; Kaplan
et al., 2014; Pun et al., 2006). MN death in ALS also involves
non-cell-autonomous mechanisms due to glial cell dysfunction
(Lobsiger and Cleveland, 2007). For instance, selective removal
of SOD1G37R in microglia (Boille´e et al., 2006), oligodendrocyte
precursor cells (Kang et al., 2013), and AS (Yamanaka et al.,
2008) slowed disease progression, suggesting that mutant
SOD1 is detrimental to glial cell functions.
Is there a role for local ventral horn AS to selectively maintain
the physiological properties and function of MN subtypes, and is
this role disrupted in ALS? We have previously shown that
ventral horn AS-encoded function of Sema3a is essential for
the survival of aMNs (Molofsky et al., 2014). Here, we focused
on the astrocytic inward-rectifying K+ channel Kir4.1 (a.k.a.
Kcnj10), which is selectively enriched in ventral compared to
dorsal spinal cord AS (Olsen et al., 2007). Kir4.1 and Kir5.1 are
the major inward-rectifying K+ channels expressed in AS and
are important for K+ homeostasis, establishing the characteristic
high resting K+ current and setting AS resting membrane poten-
tial (Djukic et al., 2007; Olsen et al., 2006; Seifert et al., 2009; Si-
bille et al., 2015). Downregulation of AS Kir4.1 has been
observed in several CNS diseases such as acute and chronic
neuroinflammation (Schirmer et al., 2014; Zurolo et al., 2012),
spinal cord injury (Olsen et al., 2010), and transgenic mouse
models of ALS (Bataveljic et al., 2012; Kaiser et al., 2006), raising
the question of whether such dysregulation is pathological or
maladaptive. Here, we report that AS Kir4.1 is specifically
required to maintain functional properties—but not survival—of
FaMN populations in the mouse spinal cord. AS Kir4.1 expres-
sion surrounding FaMNs was developmentally upregulated in a
VGLUT1-dependent manner. Conditional knockout (cKO) of
AS-encoded Kir4.1 (AS-Kir4.1cKO) led to a highly selective
and pervasive reduction in FaMN size and characteristic
electrophysiological properties. AS-Kir4.1cKO animals showed
decreased fast-twitch muscle fiber size and peak strength. In
contrast, SaMNs and gMNs showed no detectable abnormal-
ities. Viral overexpression of Kir4.1 in AS was sufficient to
increase both FaMN and SaMN soma size through activation
of the PI3K/mTOR/pS6 pathway. In cultured AS derived fromALS patient-induced pluripotent stem cells (iPSCs), we observed
significant reduction of KIR4.1 (KCNJ10) expression, suggesting
that ALS-associated SOD1 mutation causes cell-autonomous
downregulation of KIR4.1. Because AS Kir4.1 was dispensable
for FaMN survival even in the mutant SOD1 ALS mice, we
conclude that its function is required to maintain peak strength,
FaMN cellular, and biophysical properties, but not MN survival.
Collectively, these results suggest that clinical loss of peak
strength in ALS could signify downregulation of AS Kir4.1
expression and therefore be uncoupled from FaMN cell death.
RESULTS
Kir4.1 Upregulation in Ventral Horn AS
Surrounding FaMNs
To identify regions with the highest Kir4.1 expression levels, we
analyzed mRNA expression profiling data from human (GTEx-
Consortium, 2015) and mouse (Kasukawa et al., 2011) CNS.
Kir4.1 transcript levels varied by more than 5-fold across CNS
regions, with the highest expression in the spinal cord of both
humans and mice (Figures 1A and 1B), consistent with previous
studies (Nwaobi et al., 2016; Olsen et al., 2007). The spinal cord
has well-defined organization in the dorsoventral (DV) axis with
MNs located in the ventral horn (Figures 1C and 1D). Kir4.1
showed marked expression in ventral gray matter as compared
to dorsal horn in human (Figure 1C; Table S1) and mouse (Fig-
ures 1D and 1E) spinal cord. In mice, Kir4.1 was enriched in
ventral versus dorsal AS in both cultured and fluorescence-
activated cell sorting (FACS)-purified AS from Aldh1l1-GFP
mice (Cahoy et al., 2008; Tien et al., 2012) (Figure 1F).
We determined the cell-type contributions to Kir4.1 expres-
sion in the mouse spinal cord using Aldh1l1-GFP mice to label
AS along with markers of oligodendrocytes and neurons. We
found an 8-fold enrichment of Kir4.1 mRNA in FACS-isolated
AS compared to non-AS (Figure 1G), consistent with mRNA
expression profiling data from human andmouse cortex (Figures
S1A and S1B). Kir4.1 was also expressed in approximately 30%
of gray matter oligodendrocytes in the ventral horn, but not in
NeuN+ or choline acetyltransferase (ChAT)+ neurons (Figure 1D;
Figures S1C and S1D). Using MMP-9 as a marker of FaMNs
(Kaplan et al., 2014), we observed a graded expression pattern
of Kir4.1 with highest levels surrounding MMP-9+ FaMNs as
compared to MMP-9 SaMNs (Figures 1H and 1I).
As Kir4.1 function is related to synaptic activity (Cheung et al.,
2015) and neuronal signaling regulates the expression levels of
other AS transporters (Muthukumar et al., 2014; Yang et al.,
2009), we investigated Kir4.1 expression in relation to the excit-
atory presynaptic terminal markers VGLUT1 (Figures S2A–S2D)
and VGLUT2 (Figure S2E) in the developing mouse spinal cord.
We observed correlated spatiotemporal expression of Kir4.1
with VGLUT1, but not VGLUT2, expression during development
in themouse spinal cord (Figure S2). Interestingly, FaMNs have a
larger VGLUT1 synaptic density than SaMNs (Basaldella et al.,
2015), consistent with the observed higher Kir4.1 expression
levels around FaMNs (Figures 1H and 1I). To determine whether
VGLUT1 activity is required for AS Kir4.1 expression, we
analyzed VGLUT1/ conventional KO animals (Morel et al.,
2014). We found that VGLUT1 loss of function led to dramaticNeuron 98, 306–319, April 18, 2018 307
Figure 1. Kir4.1 Upregulation in Ventral Horn
AS around Large FaMN MNs
(A and B) Kir4.1 mRNA is enriched in spinal cord
compared to other CNS regions in humans (GTEx-
Consortium, 2015) (A) and mice (Kasukawa et al.,
2011) (B). Data are represented as mean ± SEM.
(C and D) Perineuronal enrichment of Kir4.1
expression in human and mouse ventral spinal
cord.
(C) KIR4.1 is expressed around SMI32+ neurons in
adult human ventral spinal cord (scale bars, 1 mm,
left; 50 mm, right). Representative image of n = 3
control human spinal cord. Patient data are
provided in Table S1.
(D) Kir4.1 is expressed around ChAT+ MNs in
mouse ventral lumbar spinal cord at P16 (scale
bars, 200 mm, left; 50 mm, right). Dotted line
denotes gray/white matter boundary. WM, white
matter. Arrowheads denote Kir4.1 enrichment
around ventral horn neurons. High-resolution
images are single-plane confocal images.
(E) Increased ventral (V) compared to dorsal (D)
Kir4.1 protein by western blot from mouse lumbar
spinal cord at P30 (n = 4 mice, mean ± SEM,
Welch’s t test).
(F) Left: fold change of Kir4.1 mRNA levels be-
tween ventral and dorsal samples from cultured
(n = 6 mice, mean ± SEM, one-sample t test)
neonatal mouse spinal cord AS. Right: FACS-
purified AS from P5 Aldh1l1-GFP+ (n = 3 mice,
mean ± SEM, one-sample t test) mouse spinal
cord.
(G) Kir4.1 mRNA levels in P5 Aldh1l1-GFP+ FACS-
purified AS compared to Aldh1l1-GFP non-AS
cells from mouse ventral spinal cord (n = 3 mice,
mean ± SEM, one-sample t test).
(H) Kir4.1 protein is preferentially found around
larger MMP-9+ FaMNs (white arrowheads)
compared to smaller MMP-9 SaMNs (yellow ar-
rowheads) at P30 (scale bar, 50 mm).
(I) Quantification of Kir4.1 signal intensity
around individual MMP-9+ or MMP-9 MN (n = 4
mice, >100 MN counts/animal, boxplot, Mann-
Whitney test).
(J) Kir4.1 loss in AS from VGLUT1 KO animals at
P26. VGLUT1 KO mice were crossed with EAAT2-
td-Tomato reporter for AS visualization.
(K) Quantification of Kir4.1 immunofluorescence
intensity per AS (EAAT2-td-tomato+) (n = 2 mice,
>50 AS counts/animal, boxplot, Mann-Whitney
test; scale bar, 40 mm, insert: 20 mm). *p < 0.05,
**p < 0.01, ***p < 0.001. Edges of boxplots denote
interquartile range (25th–75th percentile) with
whiskers denoting 1.5 times the interquartile range
and the black line denoting the median value.reduction of AS Kir4.1 expression in ventral horn (Figures 1J
and 1K). Consistent with Kir4.1 expression dictated in part by
neuron-derived factors, we found that spinal cord Kir4.1
(Kcnj10) levels were downregulated in a genetic MN ablation
model at embryonic day 18.5 (E18.5) (Figure S3). Together, these
findings suggest that AS Kir4.1 expression levels show both
regional (i.e., ventral versus dorsal horn) and subregional (i.e.,
FaMNs versus SaMNs) differences and are regulated in a
VGLUT1-dependent manner in vivo.308 Neuron 98, 306–319, April 18, 2018AS-Encoded Kir4.1 Function Is Dispensable for MN
Survival but Required for Characteristic FaMN
Morphology
The findings above suggested that AS Kir4.1 developmental
upregulation requires VGLUT1 synaptic signaling on MNs.
To investigate a requirement for AS-encoded Kir4.1 for
ventral horn MNs, we intercrossed Aldh1l1-cre, which targets
most AS in the ventral spinal cord (but not MNs, and only
30% of oligodendrocytes; Molofsky et al., 2014; Tien et al.,
Figure 2. AS Kir4.1 Is Required for Mainte-
nance of FaMN Size
(A) Left: breeding scheme. AS-Kir4.1cKO and cre-
negative control animals were bred with ChAT-GFP
mice for MN visualization. Right: total FaMN
(ChAT+/MMP-9+/NeuN+), SaMN (ChAT+/MMP-9/
NeuN+), and gMN (ChAT+/MMP-9/NeuN)
numbers are equivalent in AS-Kir4.1cKO and
cre-negative control mice at the indicated ages (n =
3 mice/group, mean ± SEM, lumbar spinal cord,
Welch’s t test).
(B, D, and F) Representative images of lumbarMNs
at P14 (B), P30 (D), and 6 months (F). Arrowheads
denote example FaMNs (scale bar, 50 mm).
(C, E, and G) Quantification of MN size at P14 (C),
P30 (E), and 6 months (G) (n = 3 mice/group, >100
MN counts/animal, boxplot, Mann-Whitney test).
(H) Schematic of retrograde labeling of MN
pools using intramuscular injection of fluorescent
cholera toxin subunit B (CTSB) in the tibialis
anterior (TA) muscle.
(I) Representative images of retrograde-labeled
ventral horn MNs in AS-Kir4.1cKO and cre-nega-
tive control mice. Arrowheads denote example
putative FaMNs (scale bar, 50 mm).
(J) Quantification of ChAT-GFP+CTSB+ MN soma
area from (G) (n = 3 mice/group, >50 MN counts/
animal, boxplot, Mann-Whitney test). *p < 0.05,
***p < 0.001. Edges of boxplots denote inter-
quartile range (25th–75th percentile) with whiskers
denoting 1.5 times the interquartile range and
black line denoting the median value.2012), with a conditional floxed allele of Kir4.1 (Djukic et al.,
2007) (Figures S4A–S4C). Aldh1l1-cre:Kir4.1fl/fl animals, here-
tofore called AS-Kir4.1cKO, survived in normal numbers up
to at least 1 year of age (data not shown). Mice were crossed
with Aldh1l1-GFP reporter animals for AS visualization. AS
Kir4.1 protein expression was undetectable in ventral horn
gray matter AS of AS-Kir4.1cKO mice compared to cre-nega-
tive controls (Figures S4A–S4C); in contrast, Kir4.1 expression
was preserved in 70% of oligodendrocytes in AS-Kir4.1cKO
animals (Figures S4A–S4C). The number of Aldh1l1-GFP+
AS was identical in AS-Kir4.1cKO and cre-negative
control mice (data not shown). RNA sequencing (RNA-seq)
of FACS-purified spinal cord Aldh1l1-GFP+ AS fromAS-Kir4.1cKO and cre-negative control
mice showed that: (1) Kir4.1 (Kcnj10)
was the most significantly downregu-
lated transcript, whereas in contrast,
(2) other AS differentiation genes,
including glutamate transporters,
showed non-significant changes (Fig-
ure S4D). Although previous work
showed that Kir4.1-dependent mainte-
nance of AS membrane potential was
required for glutamate transporter-1
(GLT-1) function (Djukic et al., 2007),
we did not find any difference in total
and GLT-1-mediated (+DHK) glutamateuptake between AS-Kir4.1cKO and cre-negative control
spinal cords (Figure S4E). These findings indicate that
Aldh1l1-cre drives AS loss of Kir4.1 function but does
not change glutamate uptake/transporter expression. More-
over, we did not observe gliosis or microglial activation at
any time points analyzed in AS-Kir4.1cKO mice (Figures
S4F–S4H).
Having confirmed AS Kir4.1 loss of function, we next
focused on consequences for MN survival. AS-Kir4.1cKO
and cre-negative controls were intercrossed with ChAT-
GFP mice for MN visualization (Figure 2A). We did not detect
losses in FaMN, SaMN, or gMN populations in the lumbar
spinal cord of AS-Kir4.1cKO mice compared to cre-negativeNeuron 98, 306–319, April 18, 2018 309
Figure 3. AS Kir4.1 Is Required for FaMN
Function, Fast-Twitch Muscle Fiber Size,
and Peak Force
(A) Breeding scheme and electrophysiology
recording schematic.
(B) Two representative current steps at 33 rheo-
base (RB).
(C–E) Rheobase (C), input resistance (D), and
steady-state (SS) firing frequency (at 33 rheobase)
(E) demonstrate altered intrinsic electrophysiolog-
ical deficits in MNs from AS-Kir4.1cKO-ChAT-GFP
animals at P12–P15 (n = 12 control MNs, n = 14
AS-Kir4.1cKO MNs from at least 3 animals per
group, boxplot, Mann-Whitney test).
(F) Input resistance versus rheobase scatterplot
shows shift in electrophysiological properties from
fast-like to slow-like in AS-Kir4.1cKO compared to
control MNs.
(G) Cross sections of TA muscle fibers immunola-
beled for marker of fast-twitch muscle (myosin
type 2) and laminin in P30 AS-Kir4.1cKO and cre-
negative control animals (scale bar, 50 mm).
(H) Quantification of TA muscle fiber cross-
sectional area (n = 3 mice/group, >100 muscle
fibers/animal, boxplot, Mann-Whitney test).
(I–K) Abnormal muscle strength behavior in
AS-Kir4.1cKO mice. Adult AS-Kir4.1cKO animals
generate less peak force (>P50, n = 14–15 mice/
group, boxplot, Welch’s t test) (I). AS-Kir4.1cKO
animals have slower front and hindlimb move-
ments as assessed by gait analysis with the
catwalk behavioral test. Swing speed corre-
sponds to the limb speed while in the air (same
animals as in I, boxplot, Welch’s t test) (J).
AS-Kir4.1cKO animals display a shorter latency to
fall on the accelerating rotarod at P30–P35 (nR 7
mice/group, mean ± SEM, two-way ANOVA,
Bonferroni post hoc test) (K). Mice performed
three trials (T, T2, and T3) per day on 3 consec-
utive days (D1, D2, and D3). *p < 0.05, **p < 0.01.
Edges of boxplots denote interquartile range
(25th–75th percentile) with whiskers denoting 1.5
times the interquartile range and black line
denoting the median value.controls at postnatal day 14 (P14), P30, and 6 months of age,
as shown in Figure 2A. Thus, AS Kir4.1 is dispensable for the
specification and survival of MNs. We next analyzed the
morphological properties of MN subpopulations (Kanning
et al., 2010). While we observed normal mature soma sizes
for all MN subtypes at P14 (Figures 2B and 2C), by P30 the
largest ChAT+ MN populations were no longer detectable in
the lumbar (L3–L6) ventral spinal cord of AS-Kir4.1cKO
mice. Indeed, we found a selective decrease in size of FaMNs
at P30 and 6 months of age, whereas the size of SaMNs and
gMNs remained unaffected (Figures 2B–2G). Retrograde
labeling with cholera toxin subunit B (CTSB) of aMNs that
innervate the tibialis anterior (TA) muscle, which contains pri-
marily fast-twitch muscle fibers (Kaplan et al., 2014),310 Neuron 98, 306–319, April 18, 2018confirmed reduced FaMN size in
AS-Kir4.1cKO animals compared to
cre-negative controls (Figures 2H–2J).Together, these findings indicate that the maintenance of
large FaMN size has a selective dependence on AS Kir4.1.
Loss of Fast Electrophysiological Signature,
Fast-Twitch Muscle Fiber Size, and Peak Strength in
AS-Kir4.1cKO Mice
The pervasive expression of AS Kir4.1 in ventral horn pre-
dicted that loss of Kir4.1 function would affect K+ homeostasis
in the region and alter physiologic function of all MN subtypes.
To test this, we performed whole-cell patch-clamp recordings
on MNs in acute lumbar spinal cord preparations from
P12–P15 AS-Kir4.1cKO and cre-negative control animals in-
tercrossed with ChAT-GFP mice for MN visualization (Figures
3A and 3B). FaMN electrophysiological properties can be
Figure 4. Cell-Autonomous AS Kir4.1 Loss Does Not Alter MN Sur-
vival in ALS
(A) Schematic of iPSC-derived AS from human SOD1D90A ALS patients and
non-ALS controls (patient data are provided in Table S2).
(B) Representative images of iPSC-derived AS from human SOD1D90A ALS
patients and non-ALS controls labeled with KIR4.1 and GFAP (scale
bar, 40 mm).
(C)KCNJ10mRNA levels are downregulated in SOD1G90A iPSC-derived AS as
compared to controls (n = 2–3 independent cultures, mean ± SEM, Mann-
Whitney test).
(D) Western blot of KIR4.1, ALDH1L1, and GFAP on iPSC-derived AS from
human SOD1D90A ALS patients and non-ALS controls.
(E) Quantification of KIR4.1, ALDH1L1, and GFAP protein levels from western
blot in (D) (n = 3/group, mean ± SEM, Mann-Whitney test).
(F) Breeding scheme used for the loss of function of AS Kir4.1 in SOD1G93A
(mSOD1) mutant background.
(G) Representative images of ventral horn lumbar spinal cord at P80 from cre-
negative control, mSOD1, andmSOD1; AS-Kir4.1cKO (mSOD1; cKO) animals
labeled with MN markers (scale bar, 50 mm).
(H and I) Quantification of ChAT+NeuN+ (H) and MMP-9+NeuN+ (I) MN numbers
in cre-negative control, mSOD1, and mSOD1; cKO animals (n = 4–7 mice/
group, >100 MN counts/animal, mean ± SEM, Kruskal-Wallis test). *p < 0.05,
**p < 0.01.classified with respect to SaMNs by their smaller input resis-
tance, larger activation threshold (rheobase), shorter afterhy-
perpolarization (AHP) half-decay time, shorter AHP amplitude,
and faster instantaneous and steady-state firing frequency
(Hadzipasic et al., 2014; M€uller et al., 2014). MNs from AS-Kir4.1cKO animals had a significantly lower activation
threshold (rheobase), larger input resistance, decreased
instantaneous and steady-state firing frequency, and
increased AHP half-decay time (Figures 3C–3E; Figures S5C
and S5D). Interestingly, these findings are consistent with
FaMN physiological dysfunction and a shift toward ‘‘slow-
like’’ properties (Figure 3F; Figures S5A and S5G). Similarly,
analysis of instantaneous firing frequency and steady-state
firing frequency (at 33 rheobase), which distinguishes slow
and fast MN properties (Hadzipasic et al., 2014), showed
that AS-Kir4.1cKO MNs are significantly more ‘‘slow-like’’
compared to control MNs (Figures S5A and S5C).
AS-Kir4.1cKO MNs displayed a left shift of the current versus
firing frequency curve in response to progressively increasing
depolarizing currents (Figure S5B), which is also consistent
with previously described ‘‘slow-like’’ MN properties (M€uller
et al., 2014). We did not observe significant differences in
the AHP amplitude (Figure S5E) or in the action potential
height (Figure S5F) or half-width (data not shown). These
findings indicate that maintenance of many FaMN biophysical
properties depends on intact AS Kir4.1 expression/function
(Figure S5G).
As previous studies have suggested a relationship between
MN area and the size of the corresponding muscle fiber subset
(Kanning et al., 2010), we analyzed fast- and slow-twitch
muscle fibers by histology. Indeed, we observed reduced fiber
areas of the TA—a predominantly fast-twitch muscle—from
AS-Kir4.1cKO mutants versus controls at P30 (Figures 3G and
3H). In contrast, slow-twitch muscle fiber size was unchanged
in these animals (Figure 3H).
We next studied the behavioral consequences of AS Kir4.1
deletion. Consistent with our observation that AS Kir4.1 was
dispensable for MN survival, AS-Kir4.1cKO adult animals did
not develop paralysis even at later time points (>1 year of age).
Because FaMNs are necessary for the generation of maximal
force output (M€uller et al., 2014), we used the grip strength test
to measure peak force. We found that AS-Kir4.1cKO animals
have decreased maximal peak force as compared with cre-
negative controls (Figure 3I). Consistent with this, AS-Kir4.1cKO
mice showed slower front and hindlimb movements (Figure 3J)
and were unable to run the fast speeds necessary to complete
the accelerating rotarod task (Figure 3K). However, AS-
Kir4.1cKOmice displayed normal spontaneous locomotor activ-
ity and basic movements in the open field test (data not
shown). Together, these results suggest that AS Kir4.1 is selec-
tively required for behavioral tasks involving strength or fast
movements.
Kir4.1 Expression Is Reduced in Human ALS AS and
Dispensable for MN Survival in SOD1G93A ALS Mice
Previous work reported a progressive decrease of Kir4.1
expression in the spinal cord of SOD1G93A ALS mice (Kaiser
et al., 2006), which exhibit a selective loss of FaMN popula-
tions (Kaplan et al., 2014; Pun et al., 2006). To ascertain
whether SOD1 mutation is sufficient to decrease KIR4.1
expression in human AS, we investigated iPSC-derived AS
from ALS patients and controls (Figure 4A; Table S2). As shown
in Figures 4B–4E, we observed significantly decreased KIR4.1Neuron 98, 306–319, April 18, 2018 311
Figure 5. Kir4.1 Viral-Mediated Overexpres-
sion Is Sufficient to Increase MN Size
(A and B) Left: schematic of intracerebroventricular
injections in neonatal mice (P2–P3) of AAV-
encoding Kir4.1-eGFP or control td-Tomato vectors
for gain-of-function (GOF) experiments (A). Right:
viral transduction of ventral spinal cord with AAV-
td-Tomato or AAV-Kir4.1-eGFP quantified in (B)
(n = 3–7 mice/group, mean ± SEM, Mann-Whitney
test).
(C) ChAT (right) and MMP-9 (left) immunofluores-
cent staining in the ventral spinal cord of AAV-
td-Tomato and AAV-Kir4.1-eGFP-injected mice.
(D and E) Quantifications of ChAT+ (D) and
MMP-9+ (E) MN soma area in P60 mice (2 months
post injection) (n = 9–13 mice/group, 70–100 MNs
counts/animal, boxplot, Mann-Whitney test, scale
bar, 40 mm).
(F) Example of MNs in contact (right) or not (left)
with Kir4.1-overexpressing AS.
(G) Ratio of soma area of MN contacting/non-
contacting transduced AS (n = 9–13 mice/group,
mean ± SEM, Mann-Whitney test). *p < 0.05,
**p < 0.01, ***p < 0.001. Edges of boxplots
denote interquartile range (25th –75th percentile)
with whiskers denoting 1.5 times the interquartile
range and black line denoting the median value.expression in cultured human AS carrying the SOD1D90A
mutation. KIR4.1 levels were downregulated both at the
mRNA level as shown by qPCR (Figure 4C) and at the protein
level showed by western blot (Figures 4D and 4E). Loss of
KIR4.1 expression in human SOD1D90A mutant iPSC-AS
appears selective, as ALDH1L1 and GFAP expression tended
toward upregulation (Figures 4D and 4E). These findings in
human patient-derived AS (in the absence of neurons) indicate
that mutant SOD1 downregulates KIR4.1 in a cell-autonomous
manner.
While AS-Kir4.1cKO did not cause MN cell death in wild-
type (WT) background mice (see above), it was possible
that AS Kir4.1 could influence cell loss in the more stressful
setting of ALS. To rule out a requirement for AS Kir4.1 to
maintain MN survival in an animal model of ALS, we assessed
MN populations in WT, SOD1G93A (mSOD1), and AS-
Kir4.1cKO, SOD1G93A (mSOD1, cKO) compound transgenic
animals (Figure 4F). In keeping with prior reports (Vinsant
et al., 2013), we observed MN loss in mSOD1 mice at
P80; however, we found no evidence for exaggerated losses
in total MN or FaMN numbers in compound transgenic
versus mice with SOD1G93A mutation alone (Figures 4G–4I).
These findings indicate that AS Kir4.1 is dispensable for MN
survival at P80 even in the setting of mutant SOD1G93A
mutation.312 Neuron 98, 306–319, April 18, 2018Kir4.1 Overexpression in Spinal
Cord AS Promotes Non-selective
Increases in aMN Size
We next used an AS-selective gain-
of-function approach in spinal cord to
evaluate the effect of Kir4.1 on MNsize. Adeno-associated viral (AAV) vectors encoding Kir4.1-
eGFP or td-Tomato under the control of an AS-specific
promoter (gfa-ABC1D) (Tong et al., 2014) were injected into
lateral ventricles in neonatal mice at P2–P3, which progresses
into the spinal canal. As shown (Figures 5A and 5B; Fig-
ures S6A–S6D), this strategy specifically promoted td-
Tomato reporter and Kir4.1-eGFP expression in spinal cord
ventral horn AS, but not neurons, microglia, or oligodendro-
cytes. AS Kir4.1 overexpression was sufficient to increase
the size of FaMNs and SaMNs at 2 months post injection (Fig-
ures 5C–5E). MNs abutting Kir4.1-eGFP-transduced AS were
significantly larger, suggesting a contact-mediated effect
(Figures 5F and 5G). We conclude that AS Kir4.1 overexpres-
sion is sufficient to increase the size of both FaMNs
and SaMNs.
AS Kir4.1 Regulates MN Size through the PI3K/mTOR/
pS6 Pathway
The PI3K/mTOR/pS6 pathway is a known regulator of neuronal
size. For example, knockout of the mTOR negative regulator
PTEN results in increased neuro-axonal size in mice (Backman
et al., 2001; Fricano et al., 2014; van Diepen et al., 2009) and in
humans (Kwon et al., 2001; Marsh et al., 1999) with Lhermitte-
Duclos disease. As shown (Figures 6A–6D), we found that
levels of the mTOR effector phosphorylated ribosomal protein
Figure 6. AS Kir4.1 Regulates MN Size
through PI3K/mTOR/pS6 Pathway
(A and C) Immunofluorescence co-staining of mTOR
downstream effector pS6 and MMP-9+ MNs in P30
AS-Kir4.1cKO LOF mice (A) and in P60 AAV-Kir4.1
GOF mice (C).
(B and D) Quantification of pS6 fluorescence in-
tensity per MMP-9+ MN (B, LOF: n = 3 mice/group,
80 MNs counts/animal; D, GOF: n = 5 mice/group,
200 MN counts/animal, boxplot, Mann-Whitney
test, scale bar, 25 mm).
(E) Rapamycin treatment in AAV-Kir4.1 GOF mice.
(F) Immunofluorescent co-staining of ChAT (left) and
MMP-9 (right) in vehicle-treated AAV-td-Tomato
and AAV-Kir4.1-eGFP mice (top two panels) or
rapamycin-treated AAV-Kir4.1-eGFP mice (lower
panel).
(G and H) Quantification of ChAT+ (G) and MMP-9+
(H) MN size in vehicle-treated AAV-td-Tomato and
AAV-Kir4.1-eGFP and rapamycin-treated AAV-
Kir4.1-eGFP mice (n = 3–4 mice/group, 100 MN
counts/animal, boxplot, Kruskal-Wallis test, scale
bar, 30 mm).
(I) Incubation of acute spinal cord slices in solutions
with high K+ concentration.
(J) Detection of ChAT-GFP+ MNs in the ventral horn
of P14 mice after 2 hr incubation in 3 mM KCl,
12 mM KCl, or 5 mM mannitol ACSF.
(K) Quantification of MN soma area in the corre-
sponding conditions (n = 4 mice/group, average
250MN counts/animal, mean ± SEM, Kruskal-Wallis
test, scale bar, 25 mm).S6 (pS6) were decreased in MMP-9+ FaMNs in P30 AS-
Kir4.1cKO (loss-of-function, LOF) mice and increased in P60
AAV-Kir4.1-injected (gain-of-function, GOF) mice. While pS6
levels tracked with MN soma area across groups, strong corre-
lation was lacking at the single-cell level, suggesting that
mTOR signaling was a driver rather than biomarker proxy of
cell size (Figure S7; STAR Methods). To determine whether
the PI3K/mTOR/pS6 pathway was necessary for the increase
in MN size observed with GOF, AAV-Kir4.1-eGFP, and AAV-
td-Tomato-injected mice were treated with the mTOR inhibitor
rapamycin or vehicle for 15 days (Saxena et al., 2013) (Fig-
ure 6E). Indeed, rapamycin treatment prevented the AAV-
Kir4.1-mediated increase in ChAT+ and MMP-9+ MN size that
were reduced to levels observed in AAV-td-Tomato controls
(Figures 6F–6H).
Previous studies have shown that Kir4.1 loss or downregu-
lation leads to deficits in AS K+ uptake (Djukic et al., 2007;
Olsen et al., 2006; Seifert et al., 2009) and increased extracel-
lular K+ (Tong et al., 2014). To address whether extracellular
K+ might directly regulate MN soma size, we incubated acute
spinal cord slices from P11–P12 WT mice in 3 mM KCl ACSF
(control), 12 mM KCl ACSF (high KCl), or 5 mM mannitol
(control for hyperosmotic solution) for 2 hr (Figure 6I). ChAT+
MNs were smaller in the high K+ condition compared with
isotonic ACSF and hyperosmotic mannitol ACSF controls,
suggesting a specific effect of K+ in regulation of cell size
(Figures 6J and 6K). These findings suggest a model whereAS Kir4.1 regulates MN morphology via PI3K/mTOR/pS6
signaling (Figure 7).
DISCUSSION
Recent studies support the emerging concept that AS func-
tional diversification is tailored to particular CNS regions to opti-
mize local neural circuit function (Ben Haim and Rowitch, 2017;
Khakh and Sofroniew, 2015; Schitine et al., 2015). Spinal MNs
display a large diversity of morphological and physiological
properties, providing a basis for selection of specialized AS
engaged in synapse modulation (Tsai et al., 2012), MN survival
(Molofsky et al., 2014), and neuronal function (Freeman and
Rowitch, 2013). Here, we found that AS-encoded Kir4.1 is
regionally distributed in the ventral horn with particular localiza-
tion surrounding FaMNs. Loss of AS Kir4.1 function led to a
selective decrease of FaMN size and to deficits in FaMN
physiological function; we observed reduced fast-twitch muscle
fiber size and peak strength without affecting FaMN survival.
Our findings show that it is possible to uncouple loss of peak
strength from FaMN death with implications for diseases like
ALS. Indeed, in other pathological conditions, AS Kir4.1 down-
regulation is associated with neuroinflammation (Nwaobi et al.,
2016), suggesting that this is a more general maladaptive
phenomenon resulting in neurological disability and might also
explain why neurological function improves with resolution of
neuroinflammatory lesions.Neuron 98, 306–319, April 18, 2018 313
Figure 7. AS-Encoded Kir4.1 Is Required for
FaMN Function and Peak Force Generation
AS Kir4.1 deletion leads to decreased FaMN size
with mTOR downregulation, loss of fast-firing MN
frequency, and decrease in fast-twitch muscle
fiber size and peak strength without affecting MN
survival.Ventral Horn AS Kir4.1 Function Indicates a Subtype-
Specific Relationship with FaMNs
Although the relative importance of AS inward-rectifying K+ chan-
nels compared to AS Na+/K+-ATPase transporters in maintaining
extracellular K+ levels is a matter of debate (for review, see Larsen
and MacAulay, 2014), it is clear that Kir4.1 is required to establish
the high K+ conductance and hyperpolarized resting membrane
potential of AS (Djukic et al., 2007; Seifert et al., 2009), which are
both important properties for the AS uptake of neuronal activity-
released K+. For example, in vivo studies have shown that Kir4.1
loss leads toalteredextracellular K+dynamics in the hippocampus
(Chever et al., 2010) and that restoration of Kir4.1 in striatal AS is
sufficient to rescueextracellular K+ increase in a transgenicmouse
model of Huntington’s disease (Tong et al., 2014). Previous work
indicated that global or glial-restricted KO of Kir4.1 (using the
hGFAP promoter) results in early animal lethality by P30 with
severe white matter pathology (Djukic et al., 2007; Neusch et al.,
2001). However, it is difficult to determine the cell-type-specific
contribution of Kir4.1 in these studies as Kir4.1 was removed
from both AS and oligodendrocytes. In our work, using Aldh1l1-
cre to target AS, we observed near total loss of Kir4.1 expression
in ventral horn AS, whereas expression in oligodendrocytes was
relatively preserved; thus, specific targeting of the astroglial line-
age with Aldh1l1-cremost likely accounts for reduced severity of
the phenotype in our study in which animals survived for at least
1 year of age.
Given the importance of AS-encoded inward-rectifying K+
channel function in homeostasis, we surmised it would be
required for optimal activity by all MN groups. However, we314 Neuron 98, 306–319, April 18, 2018were surprised to find highly MN sub-
type-specific effects of AS-Kir4.1cKO.
We found that AS-encoded Kir4.1 was
specifically needed for the function of
fast, but not slow, aMNs and that its
loss did not appear to affect gMNs. While
numbers of a- and gMNswere normal and
survival over time of all FaMNs, SaMNs,
and gMNs populations was not altered,
we observed a selective impact of
Kir4.1 loss of function on FaMNs.
AS-Kir4.1cKO resulted in biophysical
changes indicative of FaMN dysfunction,
a conclusion further supported by loss
of fast-twitch muscle mass and peak
strength. Viral-mediated overexpression
of Kir4.1 in spinal AS led to a non-selective
increase in the size of both FaMNs and
SaMNs, with a more prominent effect in
MNs directly abutting transduced AS.The fact that increased AS Kir4.1 is sufficient to promote and
maintain both slow and fast aMN size suggests that AS Kir4.1
levels are optimized to specific neuronal subpopulations and is
consistent with our observation of selective Kir4.1 upregulation
surrounding FaMNs.
Ventral Horn AS-Encoded Kir4.1 Regulates FaMN Size
through PI3K/mTOR/pS6 Signaling
The PI3K/mTOR/pS6 signaling pathway regulates metabolism
and cell size (Backman et al., 2001; Fricano et al., 2014; van Die-
pen et al., 2009). Our data indicate that Kir4.1-driven increases in
aMN size are PI3K/mTOR/pS6 pathway dependent. First,
changes in themTOR downstream effector pS6 parallel changes
in MN size in both GOF and Kir4.1 LOF models. Second, GOF
studies showed that Kir4.1-driven increase in cell size was
reversed by the mTOR inhibitor rapamycin in vivo.
Might Kir4.1 have other effects in AS relevant to MN size and
activity regulation? We took a comprehensive approach to this
question by performing an RNA-seq profiling of FACS-
purified AS from AS-Kir4.1cKO animals and control mice.
These studies showed that, apart from Kir4.1 levels itself,
Kir4.1cKO AS maintain other differentiated characteristics
in vivo. In addition, we found no evidence for astrogliosis
or microglial activation at any time points analyzed in
AS-Kir4.1cKO mice. Prior studies have shown an association
between Kir4.1 and glutamate uptake (Djukic et al., 2007;
Kucheryavykh et al., 2007); however, three lines of evidence
indicate that deficiency in glutamate uptake is unlikely to
explain the MN phenotype observed in AS-Kir4.1cKO mice.
First, we found no evidence for dysregulated glutamate
uptake in spinal cord synaptosomes from AS-Kir4.1cKO
animals—a method validated in GLT-1/ animals (Tanaka
et al., 1997)—which probably relates to the fact that GLT-1
(Slc1a2) levels and transporter currents are approximately
10-fold lower in the spinal cord compared to hippocampus
(Regan et al., 2007). Second, RNA-seq profiling of FACS-
isolated AS from AS-Kir4.1cKO and control mice showed no
difference in expression levels of glutamate transporters
GLT-1 (Slc1a2) and Glast (Slc1a3). Third, AS-Kir4.1cKO ani-
mals survived up to 1 year of age without MN degeneration
in contrast to GLT-1–/– animals (Rothstein et al., 1996; Tanaka
et al., 1997). Thus, AS Kir4.1 function does not result in
prominent secondary changes in AS gene expression and
measured glutamate uptake function. Our findings indicate
region-specific AS Kir4.1 functions that interact specifically
with FaMN populations. Such regionally adapted AS functions
might comprise a general principle underlying their diversity.
Both Intrinsic and Extrinsic Cues Regulate AS Kir4.1
Expression in Development and Disease
The extent to which AS diversity is developmentally specified
through pattern formation and/or induced locally by neuronal
cues is unclear (Ben Haim and Rowitch, 2017). For example, a
recent study showed that Purkinje neuron-derived Sonic hedge-
hog regulates AS cell fate and Kir4.1 expression in cerebellum
(Farmer et al., 2016). Indeed, we found that developmental upre-
gulation of ventral horn Kir4.1 was dependent on VGLUT1, sug-
gesting that region-specific maturation of Kir4.1 is promoted by
neuronal activity or associated factors. There might be a selec-
tive effect on Kir4.1 regulation by VGLUT1 synaptic terminal
activity onto ventral horn MNs since VGLUT1 and Kir4.1 protein
levels did not perfectly correlate in other parts of the spinal cord
(Figure S2A) and brain regions, such as the cortex, that are
known to have VGLUT1 activity but display lower levels of
Kir4.1. However, in contrast to regulation by neuron-derived
cues, AS diversification also obeys developmental patterning
in vivo (Hochstim et al., 2008; Tsai et al., 2012) and in vitro (Kren-
cik et al., 2011).
As recent studies have demonstrated that increased extracel-
lular K+ decreases mTOR signaling in T cells (Eil et al., 2016) and
that loss of AS Kir4.1 leads to increased extracellular K+ (Tong
et al., 2014), we investigated whether extracellular K+ could
directly regulate MN cell size. In acute spinal cord slices, we
found that increased extracellular K+ was sufficient to reduce
MN size, which suggests that AS Kir4.1 might regulate MN
mTOR signaling and size through extracellular K+. In addition
to K+, additional factors and mechanisms might be at play in
Kir4.1-mediated MN size regulation. Indeed, Kir4.1 expression
is selectively enriched in AS processes contacting MN soma,
and MN size increase in Kir4.1 GOF mice was prominently in
MNs directly abutting transduced astrocytes, suggesting that
Kir4.1 effects could be partly contact mediated. Biophysical
modeling studies have shown that AS Kir4.1 is particularly
important for K+ clearance during high levels of neuronal activity
(Sibille et al., 2015), which corresponds to the FaMN electro-
physiological signature. These MNs also have a larger VGLUT1
synaptic density than SaMNs (Basaldella et al., 2015). Hence,there might be an AS-MN subtype-specific crosstalk in the
ventral spinal cord, where FaMN high activity/high VGLUT1
innervation drives AS Kir4.1 expression, which in turn decreases
extracellular K+ and modulates intrinsic MN mTOR signaling to
control MN size.
Moreover, our study provides evidence that Kir4.1 is regulated
in AS in a cell-autonomous manner. First, in vitro cultures with
purified AS derived from neonatal spinal cord maintained ventral
enrichment of Kir4.1 levels in the absence of neurons. Second, in
cultured human iPSC-derived AS, we found that mutant SOD1
exerted cell-autonomous effects to downregulate KIR4.1. These
findings suggest that interplay between intrinsic and extrinsic
factors is needed to achieve optimal Kir4.1 expression during
development. We speculate that patterning results in early rela-
tive upregulation of Kir4.1 in ventral AS domains and perhaps
primes AS to detect neuronal activity-dependent cues that
determine physiological Kir4.1 levels critical to maintain FaMN
function and peak strength. It follows that maladaptive downre-
gulation of Kir4.1 in disease would disrupt this support mecha-
nism with functional compromise of FaMNs.
AS-Encoded Kir4.1 Uncouples Loss of Peak Strength
from FaMN Death
MN cell death is an irreversible step of clinical decline in ALS.
FaMNs have been shown to be vulnerable in SOD1G93A mice
(Kaplan et al., 2014; Pun et al., 2006; Saxena et al., 2009). For
example, loss of function of the FaMN-specific marker MMP-9
delays disease progression while its overexpression in FaMNs
accelerated TA denervation (Kaplan et al., 2014). Several studies
indicate that mouse model and ALS patient-derived MNs have
physiological alterations including intrinsic hyperexcitability
(Devlin et al., 2015; Wainger et al., 2014), hypoexcitability
(Sareen et al., 2013), or some combination depending on matu-
rational state (Devlin et al., 2015) with still some considerable
debate about what occurs in vivo (Sances et al., 2016). In gen-
eral, altered MN excitability is thought to contribute to chronic
MN dysfunction as a common pathogenic feature in ALS.
By focusing on roles of AS, our study helps clarify the conse-
quences of alterations in MN excitability and the importance of
AS-encoded factors in regulating the clinical phenotype of
peak strength in the following ways. First, while conditional KO
of Kir4.1 in AS leads to an early dysregulation of MN excitability,
we failed to observe any signs of MN loss through at least
6 months of age. This analysis contained counts of total MN
numbers including FaMNs, SaMNs, and gMNs. These findings
make the points that (1) alterations in MN excitability in ALS
could be linked to impaired K+ buffering by AS that down-
regulate Kir4.1 channels and (2) excitability dysregulation in
AS-Kir4.1cKO animals is insufficient to cause MN cell death.
Indeed, crossing AS-Kir4.1cKO into the SOD1G93A mutant
background failed to accelerate MN loss in this animal model,
suggesting that Kir4.1 is not essential for MN survival even in
the setting of ALS. Second, loss of peak strength can be
accounted for by AS-encoded Kir4.1 downregulation. Kir4.1
expression is reduced in both mouse and rat SOD1G93A
models in vivo (Bataveljic et al., 2012; Kaiser et al., 2006), and
in this study, we found that iPSC-derived AS from ALS patients
show significant loss of Kir4.1 expression in vitro. Furthermore,Neuron 98, 306–319, April 18, 2018 315
as stated above, loss of Kir4.1 in AS causes a decrease of peak
strength in the absence of MN cell death. Together, these find-
ings suggest that loss of AS Kir4.1 in ALS is maladaptive and
might underlie the initial clinical presentation of weakness. It
follows that loss of peak strength early in the ALS disease
course might represent pathology caused by Kir4.1 down-
regulation in AS. If so, this potentially ‘‘reversible state’’ could
be treatable by gene overexpression to promote Kir4.1 expres-
sion in ventral horn AS to assuage muscle weakness. Together,
these findings suggest the consequences of AS Kir4.1 loss on
MN function in ALS and neuroinflammatory conditions.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human Spinal Cord Tissue
All tissue was provided by the UK Multiple Sclerosis Tissue Bank at Imperial College, London (Table S1). Tissue was obtained via a
prospective donor scheme following ethical approval by the National Research Ethics Committee (08/MRE09/31).
Mice
All mouse strains were maintained at the University of California, San Francisco (UCSF) specific pathogen-free animal facility and all
animal protocols were approved by and in accordance with the guidelines established by the Institutional Animal Care and Use
Committee and Laboratory Animal Resource Center. Aldh1l1-GFP transgenic mice were generated by the GENSAT project (Gong
et al., 2003). The same methods and technology were used to generate Aldh1l1-cre mice as previously described (Tien et al.,
2012). Kir4.1fl/fl mice were obtained from Dr. Ken Mc Carthy (University of North Carolina, Chapel Hill). The EAAT2-td-Tomato trans-
genic mice were generated as previously described (Yang et al., 2011). The VGLUT1 KO mice were a gift from Dr. Robert Edward
(University of California, San Francisco) (Fremeau et al., 2004). ChAT-GFP (MGI: 3694555) mice were a gift from Dr. Roger Nicoll
(University of California, San Francisco) (Tallini et al., 2006). SOD1G93A and B6SJL control mice (Stock No: 002726) were obtained
from The Jackson Laboratory. All miceweremaintained on a 12 hr light/dark cycle with food andwater available ad libitum. Micewere
gendermatched for all experiments except for experiments using SOD1G93Amice, where onlymaleswhere used.Micewere kept on
a mixed background and littermate controls (either WT or cre-negative) were used for all experiments.
Human iPSC Lines
Human iPSCs-derived AS were obtained from either two or three healthy control lines or a patient carrying the SOD1D90A mutation
(Sposito et al., 2015). These lines included an isogenic control line (SOD1D90D) and its mutant pair (generated and provided by Prof.
Su-Chun Zhang; Chen et al., 2014) (Table S2).
METHOD DETAILS
Viral Vectors, Injections, and Pharmacological Treatment
Adeno-associated viral vectors targeting AS encoding td-Tomato (AAV2/9-gfaABC1D-Td-Tomato) or Kir4.1-eGFP (AAV2/9-
gfaABC1D-Kir4.1–eGFP) (Tong et al., 2014) were produced from Addgene plasmids (#52874 and #44332) by the University of
Pennsylvania viral core. Wild-type (B6SJL background) pups (P2-P3) received icv injections of AAV-td-Tomato or AAV-Kir4.1-eGFP.
Anesthesia was induced by hypothermia (3-5 min on ice) and injections were performed using a custom-made neonate stereotactice3 Neuron 98, 306–319.e1–e7, April 18, 2018
frame with beveled glass needles (5 mL, wiretrol, Drummond). Viral vectors were injected in the lateral ventricles (coordinates from
Lambda: lateral: +0.6 mm/antero-posterior: 1.2 mm/ventral from the skull: 1.8 mm) at a total titer of 9.1010 genome copies in
3 mL (2 mL right hemisphere, 1 mL left hemisphere). The needle was left in place for 3 min after injection and pups were rubbed in the
litter before them putting back into the home cage. For pharmacological inhibition of the mTOR pathway, AAV-Kir4.1-eGFP or
AAV-td-Tomato-injected mice received intraperitoneal injections of either Rapamycin (6 mg/kg) or vehicle for 15 days (one injection
every second day) as previously described (Saxena et al., 2013). Animals were randomly allocated into experimental groups.
Immunohistochemistry
Micewere either transcardially perfusedwith ice-cold PBS and either perfused or samples post-fixed in 4%paraformaldehyde (PFA).
After post-fixation in 4% PFA, samples were cryoprotected in 30% sucrose for 48 hr at 4C and embedded in optimal cutting tem-
perature (OCT) compound (Tissue-Tek). Cryosections (14-16 mm) were collected on superfrost slides (VWR) using a cryostat
(CM3050S, Leica). Cryosections were subjected to heat-induced antigen retrieval in 10mM sodium citrate (pH = 6) or 1X Dako Target
antigen retrieval solution for 2 min at 95C, permeabilized and blocked in 0.1M PBS/0.2% Triton X-100/10% serum for 1 hr at room
temperature (RT). Primary antibody incubations were carried out overnightcat 4cC. After washing in 0.1M PBS, cryosections were
incubated with secondary antibodies diluted in 0.1MPSB/0.2% Triton X-100/10% serum for 1 hr, RT. Donkey or horse serums were
used for incubations. Goat or donkey Alexa fluochrome-tagged secondary IgG antibodies were used for primary antibody detection.
Slides were mounted with DAPI Fluoromount-G (SoutherBiotech). Primary antibodies used included: goat ChAT (AB144P, Millipore,
1:200), rabbit DsRed (632496, Clonetech, 1:500), rat GFAP (13-0300, Invitrogen, 1:1000), chicken GFP (GFP-1020, Aves, 1:500),
rabbit Kir4.1 (APC035, Alomone, 1:2000), rabbit laminin (L9393, Sigma, 1:1000), goat MMP-9 (M9570, Sigma, 1:500), mouse Myosin
type 1 (M8421, Sigma, 1:4000), mouseMyosin type 2 (M4276, Sigma, 1:400), mouse NeuN (MAB377, Millipore, 1:1000), Purified anti-
Neurofilament H (NF-H), Nonphosphorylated Antibody (SMI32, 801701, Biolegend, 1:10 000), guinea pig VGLUT1 (AB5905,Millipore,
1:5000), guinea pig VGLUT2 (AB2251, Millipore, 1:5000). Images were acquired on a Leica TCS SPE laser confocal microscope with
either 20x or 40x objectives; all pictures are z stack confocal images, unless stated otherwise.
Immunocytochemistry
For immunocytochemistry (ICC), hiPSC-AS were plated onto Geltrex coated round glass coverslips (diameter: 13 mm) and fixed in
4% PFA for 10 min, RT. Standard ICC protocols were followed. Briefly, samples were permeabilized and blocked in 0.1M PBS/0.3%
Triton X-100/5% normal goat serum for 1 hr. Primary antibodies were applied overnight at 4C in the same blocking solution. Primary
antibodies usedwere rabbit Kir4.1 (Alomone, APC035, 1:2000) andmouseGFAP (Sigma, 1:500). Secondary antibody incubation was
performed for 1 hr, RT, using specie-specific Alexa fluochrome-tagged secondary IgG antibodies and nuclei were counterstained
with DAPI. Samples were imaged using a Leica DM5500B microscope with a 63x objective.
Muscle Histology and Analysis
Tibialis anterior (TA) muscle was isolated after transcardial perfusion of mice with ice-cold PBS and then snap frozen in OCT with
liquid nitrogen. Transverse cryosections of TA were prepared and tissue was fixed on slide with 4% PFA for 10 min, RT prior to
immunostaining as described above. Muscle fiber area was quantified by tracing the laminin signal in ImageJ from confocal images
obtained with a 20x objective.
Motor Pool Labeling
We used intramuscular injections of Cholera Toxin Subunit B (CSTB)-Alexa Fluor 594 Conjugate (Thermofisher) for retrograde label-
ing of motor pools in the spinal cord.AS-Kir4.1cKO or control mice (P30) were injectedwith 20 mL (5 individual injection sites) of CTSB
in the right TA muscle. Mice were perfused 5 days later and spinal cords processed for histology as described above.
Flow Cytometry
Postnatal day 5 (Figure 1) spinal cords were microdissected using an ‘‘open book’’ preparation to separate dorsal and ventral
pieces (Molofsky et al., 2014). Whole spinal cord was dissected at P12-14 for RNA-sequencing (Figure S4D). Tissue dissociation
was performed as described previously (Cahoy et al., 2008). Briefly, tissue was collected in HBSS without Ca2+ and Mg2+ and trans-
ferred to dissociation buffer (glucose 22.5 mM, EDTA 0.5 mM, phenol red), papain (20 U mL1, Worthington), L-cysteine (1 mM),
DNase (125 U/mL) for 80 min at 33C. Tissue was then washed in dissociation buffer containing ovomucoid (1.0 mg/mL), centrifuged
5min at 200 g. Supernatant was removed, tissue resuspended in the same buffer and mechanically disrupted using a P1000 pipette.
Dissociated cells were layered onto dissociation buffer with concentrated ovomucoid (5 mg/mL). Samples were centrifuged 5 min at
200 g and pellet resuspended in staining medium with DAPI. Aldh1l1-GFP+ and Aldh1l1-GFP cells were sorted as previously
described (Molofsky et al., 2013) on a BD FACS Aria II and gated on forward/side scatter, live/dead by DAPI exclusion, and GFP,
using GFP and DAPI controls to set gates for each experiment.
Astrocyte Cell Culture
Ventral and dorsal spinal cords from P0-1 mice were isolated and dissociated as above and described previously (Molofsky et al.,
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5 mg/mL1 N-acetylcysteine, 2 mg/mL1 insulin and 20 ng/mL1 EGF. Six days after plating cells, flasks were shaken to remove
oligodendrocyte contamination. At 8 days, AraC was added to kill rapidly proliferating cells. 10–12 days after initial plating, RNA
was collected for Kir4.1 qPCR analysis. Animals were randomly allocated into experimental groups.
Human iPSC Culture and AS Differentiation
Human hiPSCs were maintained on Geltrex (Life Technologies) with Essential 8 Medium media (Life Technologies) and passaged
using EDTA (Life Technologies, 0.5 mM). For the in vitro assays and western blot three cultures of human AS were used for each
group, which derived from three separate inductions of hiPSCs, using two healthy control lines and a patient carrying the SOD1D90A
mutation (Sposito et al., 2015) (Table S2). For qPCR we used three independent AS cultures for each group deriving from hiPSCs of
three healthy controls and two patients with the SOD1D90A mutation. These lines included an isogenic control line (SOD1D90D) and
itsmutant pair (Chen et al., 2014) (Table S2). Spinal AS differentiation was carried out as previously published (Hall et al., 2017; Tyzack
et al., 2017).
RNA Sequencing and Analysis
Total RNA from FACS AS was extracted with Trizol (Invitrogen) and purified using the RNeasy Kit (QIAGEN). cDNA was generated
from full-length RNA using the NuGEN RNA-Seq V2 kit which uses the single primer isothermal amplification method to deplete
ribosomal RNA, and sheared by Covaris to yield uniform size fragments. The NuGen Ultralow kit was used to add adapters,
barcoding, and amplification. Library was purified using Agencourt XPmagnetic beads, quality controlled with an agilent bioanalyzer,
and quantified by qPCR. Eight libraries were pooled per lane for single end (SE75) sequencing. Over 51M reads were sequenced per
sample (range 38-66M reads) using a NextSeq 500.
Read quality was assessed using fastqc (version 0.11.4) (Andrews, 2010) and the first 5 bases as well as the last base of each
readwere trimmed and aligned to theMusmusculus genome (Ensembl GRCm38) (Aken et al., 2016) using TopHat2 (version 2.0.11)
with bowtie2 (version 2.2.3) (Kim et al., 2013). TopHat2 was run with the following arguments ‘‘–no-coverage-search–segment-
mismatches 1’’ with the genes.gtf file from Ensembl GRCm38. Gene counts were created from the alignment files using SAMtools
(version 0.1.19) (Li et al., 2009) to generate BAM files and subsequently htseq-count (version 0.6.1p1) with default parameters
(Anders et al., 2015) to create count files. From raw count files, DESeq2 (Love et al., 2014) was used to detect differentially
expressed genes. FPKM values were generated using cuffquant and cuffnorm from the cufflinks suite of software tools (Trapnell
et al., 2010).
qPCR Analysis
RNA was isolated using Trizol reagent (Invitrogen), DNase-digested to remove genomic DNA, and purified using the RNAeasy Kit
(QIAGEN) according tomanufacturer’s instructions. ComplementaryDNAwas generated using Superscript III (Invitrogen) and random
hexamers. Primers used included kcnj10 (forward: GTCGGTCGCTAAGGTCTATTACA; reverse: GGCCGTCTTTCGTGAGGAC) and
b-actin (forward: TGGATCGGTGGCTCCATCCTGG; reverse: GCAGCTCAGTAACAGTCCGCCTAGA). qPCR was performed on a
LightCycler 480 using LightCycler 480 SYBR Green I Master mix and melting curves were analyzed to ensure primer specificity.
Western Blot
Dorsal and ventral spinal cord (Figure 1E) samples were microdissected from acute slices prepared in the samemanner as done for
electrophysiology (see below). Sample lysis was performed in RIPA buffer (Thermofisher) in the presence of protease and phospha-
tase inhibitors (Cell signaling). Samples concentration was determined with the Bradford method and protein migration and gel
transfer was performed as described previously (Kenney and Rowitch, 2000). After blocking in Odyssey Blocking Buffer (PBS)
(Li-Cor) for 1 hr, RT, primary antibodies were incubated O/N at 4C onto the western blot membrane. The following antibodies
were used: rabbit Kir4.1 (extracellular, APC-165, Alomone, 1:2000), rabbit Kir4.1 (APC035, Alomone, 1:2000), mouse GFAP (Sigma,
1:500), rabbit ALDH1L1 (ab87117,Abcam, 1:500), mouse b-actin (Sigma, A5441, 1:5000 or AC-74, 1:20000). IRDyeGoat anti-mouse
and anti-rabbit (680 and 800) fluorescent secondary antibodies (Li-Cor) were used for protein detection on the Odyssey Cxl imaging
system.
Glutamate Uptake Assay
Glutamate uptake was performed with crude synaptosome preparation from adult (3-6 months) mouse spinal cord using 0.32M
sucrose centrifugation method (Robinson et al., 1991). After total protein determination, 1mCi L-3H glutamate and 100mM non-
labeled glutamate were mixed with Na+ uptake buffer (total volume 275 mL) then added into 25 mL of each synaptosome sample
in 96-well multiscreen HTS filter plates (Millipore). After 6 min incubation, uptake was terminated by putting into ice bath. Samples
were then filtered using the Steriflip vacuum filtration system (Millipore) and washed 6X with ice-cold PBS while continue filtering the
samples. Each filtered 96-well membrane was excised out and transferred for scintillation counting. DL-threo-b-Benzyloxyaspartic
acid (DL-TBOA, 500 mM) was added into appropriate wells in glutamate uptake assay. Disintegration per min (DPM) value was
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Whole-Cell Patch-Clamp Recordings
Acute fresh lumbar (L3–4) spinal cord slices were prepared from Aldh1l1-cre:Kir4.1fl/fl:ChAT-GFP mice and Cre-negative littermate
controls from P12–14 using previously described protocols and solutions (Mitra and Brownstone, 2012). In brief, transverse slices
(350-mm thick) were cut with a vibratome (Leica Microsystems) in a chamber filled with ice-cold sucrose cutting solution (in mM:
191 sucrose, 0.75 K-gluconate, 1.25 KH2PO4, 26 choline bicarbonate (80% solution), 4 MgSO4, 1 CaCl2, 20 dextrose, 2 kynurenic
acid, 1 (+)-sodium l-ascorbate, 5 ethyl pyruvate, and 3 myo-inositol) followed by a brief (60 s) incubation in polythethylene glycol
(Mn = 1,900–2,200). The slices were then incubated in cutting solution at 35C for 30 min followed by 30min in artificial cerebrospinal
fluid (in mM: 121 NaCl, 3 KCl, 1.25 NaH2PO4, 25 NaHCO3, 1.1 MgCl2, 2.2 CaCl2, 15 dextrose, 1 (+)-sodium l-ascorbate, 5 ethyl
pyruvate, and 3myo-inositol) then equilibrated to room temperature. All bicarbonate-buffered solutions were bubbled with carbogen
for at least 30 min prior to use and continuously throughout their usage. Whole-cell recordings were made using patch clamp
amplifiers (Multiclamp 700B) under an infrared-differential interference contrast microscope. Data acquisition and analysis were
performed using digitizers (DigiData 1440A) and analysis software pClamp 10 (Molecular Devices). Signals were filtered at 6 kHz
and sampled at 20 kHz. Glass pipettes with a resistance of 2.5–4 MU were filled with a K-methanesulphonate internal solution
(in mM: 131 K-methanesulfonate, 6 NaCl, 0.1 CaCl2, 1.1 EGTA-KOH, 10 HEPES, 0.3 MgCl2, 3 ATP-Mg
2+ salt, 0.5 GTP-Na+ salt,
2.5 l-glutathione reduced, and 5 phosphocreatine di(tris) salt; the solution was adjusted to a pH of 7.25 with KOH). Series resistance
(15–25MU) wasmonitored throughout thewhole-cell recording and data were discarded if the change in series resistance was >20%
during the course of the experiment.
Afterhyperpolarization (AHP) amplitude and decay time were calculated from the 25 pA depolarizing step protocol (the minimum
step at which action potentials occurred). AHP amplitude was determined from the voltage difference between the beginning of the
action potential and the minimum of the AHP. AHP half-decay time was determined as half the time from the minimum of the AHP to
its resolution.
High KCl Acute Spinal Cord Slice Experiment
Acute spinal cord slices from P11-P12 mice were obtained as described in the above paragraph. After incubations in the cutting
solutions and regular ACSF, slices were transferred onto culture inserts (Millipore) in 6-well plates and incubated for 2 hr at 37C
in the following solutions: control ACSF (3 mM KCl), high KCl ACSF (12 mM KCl) or 5 mM mannitol ACSF as a control for hypertonic
ACSF solution (3-4 lumbar spinal cord slices were incubated per well per condition).
Behavioral Analysis
All behavioral experiments were performed at the UCSF Neurobehavioral Core for Rehabilitation Research. Peak force, gait analysis,
and the open field test were done on the same cohort of adult animals, whereas the rotarod test was performed on a different cohort
of P30 animals. Maximum limb force was determined by measuring mouse forelimb grip strength using a force transducer (Ametek).
The grip strength of each mouse was measured four times each day, and the highest measured value was scored. The test was per-
formed on five consecutive days, fromwhich the averagemaximum force per animal was computed. The Catwalk apparatus (Noldus)
consists of a 1.3 m glass plate and two side barriers, forming a straight tunnel. In a dark room, themouse walks across the glass plate
and a high-speed camera from underneath captures its footprints. The animal’s home cage was placed at one end of the glass plate
and the animal was placed on the opposite end, allowing it to walk freely across the runway into its home cage. A training period of
two days was used to acclimatize the animals to the training apparatus and to train the animals in the task. On the third day, three
complete trials were recorded per animal. A trial was regarded as complete if the animal walked across the recorded area without
stopping significantly or turning around. Gait analysis and verification of each recorded trial was done manually using CatWalk
7.1 software. The open field test (Kinder-Scientific) was used to assay overall locomotor activity. The field was divided up into zones
monitored by video tracking software. Data collected includes active time, distance traveled, rearing time, time along the perimeter of
the field, and time spent in the center. Each mouse was tested in the open field apparatus undisturbed for 10 min. The rotarod
(Ugo Basile) test was performed on a rotating rod that accelerated from 0-40 rotations per minute (rpm) in during a 5-min period
in order to assess for motor deficits. The task requires the mouse to balance on the rod and the time on the rod over the session
is recorded. Animals were tested 3 times per day for 3 consecutive days. All behavioral studies were carried out with the experimenter
blind to genotype.
Regional mRNA Bioinformatics Analysis
For the human regional Kir4.1mRNA analysis, RPKMexpression data fromGTExwere downloaded from their data portal (gtexportal.
org, V6 data release). We detected a large batch effect for GTEx (GTEx-Consortium, 2015) samples due to center acquisition
site using the SampleNetwork R function (Oldham et al., 2012). We therefore restricted our analysis to samples acquired by centers
‘B1, A1’ or ‘C1, A1’. For the mouse regional Kir4.1mRNA analysis, raw profiling. CEL files were obtained from the Gene Expression
Omnibus website from the GEO: GSE16496 (Kasukawa et al., 2011) accession ID. Expression values were generated in R using the
expresso function of the affy R package with ‘‘mas’’ settings and no normalization. Expression values were also quantile normalized
(Bolstad et al., 2003) using the SampleNetwork R function.Neuron 98, 306–319.e1–e7, April 18, 2018 e6
QUANTIFICATION AND STATISTICAL ANALYSIS
Motor Neuron Soma Size and Count Analysis
Motor neuron soma size and counts were performed on maximal intensity projections of 10 mm z stacks with a 2 mm z-step of lumbar
(L3-L6) levels on 2-4 sections per animal. Soma size was determined by tracing the ChAT-GFP signal using ImageJ software. Mea-
surements were performed on the optical section with the largest soma area and only on motor neurons that had a DAPI nucleus
visible. Similarly, motor neurons were only counted if a DAPI+ nucleus was present. Phopho-S6 fluorescence intensity (IR) was
measured using the mean gray value function on ImageJ within a ROI delineating individual fast MMP-9+ MN soma, which assures
value normalization according to the size of the selected area (i.e., MN soma). In addition, as immunofluorescence intensity can vary
between sets of experiments (for example, depending on tissue fixation), the absolute values of pS6 IR were normalized to the value
in their respective internal controls ( =1) for both LOF and GOF experiments. Quantifications were performed on 40x confocal images
(12 mm z stack, 1 mm z-step) at the lumbar (L3-L6) spinal cord levels on 5-8 sections per mouse. For the contact/non-contact soma
area ratio quantification, MN soma area was quantified on merged images with transduced astrocytes in both groups. A potential
limitation to this analysis is the fact that contact was defined based on 16 mm-thick sections. There may still be contact from astro-
cytes out of the section, which could inflate the observed effect in what we are labeling as non-contacted MNs. All quantifications
regardingMNnumber and soma areawere performed under blind conditions for experimental group (genotype, viral vectors injection
or treatment groups).
Astrocyte and Synaptic Puncta Quantification
For AS Kir4.1 intensity quantification in Aldh1L1-GFP-labeled AS (Figure S2C), we quantified signal on maximal intensity projections
of 10 mm z stacks with a 1 mm z-step using cellular areas centered on Aldh1l1-GFP+ AS somas in ImageJ, since Aldh1l1-GFP signal is
restricted to the soma and primary processes. Synaptic area coverage of VGLUT1 and VGLUT2 synapses were similarly obtained
from maximal intensity projections of 10 mm z stacks with a 1 mm z-step using the analyze particle function in ImageJ. Thresholds
were set identically for each image. For AS Kir4.1 intensity measurements in EAAT2-Td-Tomato-labeled AS (Figures 1J and 1K),
3D reconstruction was performed on 10–12 mm z -stacks with a 0.5–1 mm z-step using the surface tool in Imaris software, as
previously described (Morel et al., 2014). The volume of individual AS can be directly measured from generated 3D domains in Imaris.
To quantify Kir4.1 signal within each AS domain, individual domains were masked onto the Kir4.1 channel by setting all pixel signals
outside the masked cell domain to zero so that only Kir4.1 signal within the masked AS domain remained. The Kir4.1 signal for each
AS domain was quantified using ImageJ software. For AAV transduction quantification, td-Tomato+ or GFP+ area was normalized to
the ventral horn total area. The mean fluorescence intensity was also quantified in the ventral spinal cord for the two groups.
Statistical Analysis
We did not perform statistics to pre-determine group sample size. However, the sample sizes used were similar to previously
published studies by our group and others. All biological replicates (n) are derived from at least three independent experiments
(except for the VGLUT1 KO experiment, n = 2). Unless otherwise specified, no data were excluded from analysis. All bar graphs
are expressed as mean ± SEM. The normality of the data points was verified using the Shapiro-Wilk test and for variables that dis-
played normal distributions an unpaired Welch’s t test to compare the difference in means between two groups. Two-way ANOVA
tests and Bonferroni post hoc tests were used for the rotarod experiment (Figure 6). When normality tests failed, non- parametric
Mann-Whitney (two groups) or Kruskal-Wallis (more than groups) tests were used. All statistical tests were performed using the R
software environment.
DATA AND SOFTWARE AVAILABILITY
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